See more : Better World Acquisition Corp. (BWACU) Income Statement Analysis – Financial Results
Complete financial analysis of Arcturus Therapeutics Holdings Inc. (ARCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcturus Therapeutics Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Altamira Therapeutics Ltd. (EARS) Income Statement Analysis – Financial Results
- Shalimar Productions Limited (SHALPRO.BO) Income Statement Analysis – Financial Results
- Millennium Sustainable Ventures Corp. (MILC) Income Statement Analysis – Financial Results
- Bombardier Inc. (BBD-PC.TO) Income Statement Analysis – Financial Results
- Church & Dwight Co., Inc. (0R13.L) Income Statement Analysis – Financial Results
Arcturus Therapeutics Holdings Inc. (ARCT)
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.75M | 205.76M | 12.36M | 9.54M | 20.79M | 15.75M | 13.00M | 20.38M | 6.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.96M | 143.05M | 171.86M | 55.95M | 32.44M | 16.98M | 410.00K | 294.00K | 51.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 154.79M | 62.70M | -159.50M | -46.41M | -11.65M | -1.23M | 12.59M | 20.09M | 6.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.13% | 30.48% | -1,290.57% | -486.50% | -56.04% | -7.80% | 96.85% | 98.56% | 99.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 192.13M | 147.75M | 173.76M | 57.85M | 33.64M | 16.98M | 15.92M | 18.39M | 13.46M | 25.11M | 7.07M | 818.00K | 1.82M |
| General & Administrative | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Other Expenses | 0.00 | -244.00K | 0.00 | 0.00 | 0.00 | 0.00 | -348.00K | 1.42M | 1.25M | 2.13M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 235.95M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Cost & Expenses | 245.00M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Interest Income | 17.36M | 2.58M | 753.00K | 470.00K | 408.00K | 514.00K | 89.00K | 798.00K | 338.00K | 239.00K | 22.00K | 2.00K | 21.00K |
| Interest Expense | 767.00K | 420.00K | 2.67M | 361.00K | 446.00K | 186.00K | 150.00K | 295.00K | 251.00K | 2.00K | 197.00K | 80.00K | 44.00K |
| Depreciation & Amortization | 2.96M | 1.53M | 1.19M | 882.00K | 684.00K | 582.00K | 410.00K | 294.00K | 51.00K | 31.00K | 8.00K | 7.00K | 6.00K |
| EBITDA | -24.17M | 13.70M | -201.66M | -70.64M | -24.42M | -20.72M | -10.34M | -947.00K | -1.72M | -32.81M | -10.28M | -1.51M | -3.92M |
| EBITDA Ratio | -15.32% | 5.67% | -1,621.42% | -752.56% | -122.88% | -133.42% | -79.56% | -123.18% | -320.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.21M | 12.18M | -202.85M | -71.52M | -25.51M | -21.81M | -10.49M | -25.17M | -19.70M | -33.08M | -10.29M | -1.50M | -3.91M |
| Operating Income Ratio | -49.58% | 5.92% | -1,641.33% | -749.81% | -122.72% | -138.46% | -80.72% | -123.48% | -320.92% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 50.32M | -1.53M | -822.00K | -624.00K | -478.00K | 26.00K | -409.00K | -536.00K | 11.00K | 227.00K | -197.00K | -78.00K | -23.00K |
| Income Before Tax | -27.89M | 10.64M | -203.67M | -72.15M | -25.99M | -21.79M | -10.90M | -24.53M | -19.40M | -32.85M | -10.49M | -1.58M | -3.93M |
| Income Before Tax Ratio | -17.68% | 5.17% | -1,647.98% | -756.35% | -125.02% | -138.29% | -83.87% | -120.35% | -316.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.84M | 1.30M | 3.19M | -784.00K | -270.00K | 212.00K | 1.00K | 73.00K | 51.00K | -17.00K | 61.00K | 65.00K | 21.00K |
| Net Income | -29.73M | 9.35M | -206.86M | -71.36M | -25.72M | -21.79M | -10.90M | -24.60M | -19.45M | -32.83M | -10.55M | -1.58M | -3.93M |
| Net Income Ratio | -18.84% | 4.54% | -1,673.78% | -748.13% | -123.72% | -138.29% | -83.87% | -120.71% | -316.86% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| EPS Diluted | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| Weighted Avg Shares Out | 26.63M | 26.45M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
| Weighted Avg Shares Out (Dil) | 26.63M | 27.09M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
3 Biotech Stocks to Buy Before the Breakout
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
3 Biotech Stocks for Getting Rich in 2023
Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?
Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
GROUPE SANTÉ DEVONIAN ANNONCE LA NOMINATION DE NOUVEAUX MEMBRES AU CONSEIL D’ADMINISTRATION ET L’ATTRIBUTION D’OPTIONS D’ACHAT D’ACTIONS
Source: https://incomestatements.info
Category: Stock Reports